Peptide Regulation Watch · Status Board
Where the peptides actually stand.
The regulatory status of the substances this market runs on — verified against the primary record, dated, and labeled. Fact and interpretation are not the same thing, and neither is a recommendation and a rule. This board states only what has been verified; everything else is listed as under review.
All statuses as of August 22, 2026 — regulatory facts have a shelf lifeThe board
Every row: verified status, the date it was checked, and what the record shows.
| Substance | Status | The record |
|---|---|---|
| BPC-157 | Not permitted | Not lawful to compound for human use via any pathway. The July 23–24 PCAC recommendation is advisory; no FDA rulemaking since. Not on the 503B bulks list. |
| TB-500 | Not permitted | Same posture — among the six from the July vote. Advisory recommendation only. |
| KPV | Not permitted | Among the six from the July vote. Advisory recommendation only. |
| MOTS-c | Not permitted | Among the six from the July vote. Advisory recommendation only. |
| Epitalon | Not permitted | Among the six from the July vote. Advisory recommendation only. |
| Semax | Not permitted | Among the six from the July vote. Advisory recommendation only. |
| Semaglutide (compounded) | Wind-down | Enforcement discretion ended after shortages resolved; FDA sent warning letters to 30 telehealth companies on Feb 20, 2026. |
| Tirzepatide (compounded) | Wind-down | Same posture as compounded semaglutide. |
| Sermorelin | Not listed | Not on FDA’s 503A nominations list (updated 5/14/26) — in any category. The widely quoted Category 1 status does not match the record; no enforcement-discretion assurance attaches. |
| Thymosin alpha-1 | Not listed | Not in Category 1 — sits in the withdrawn-nominations table on FDA’s safety-risks page. The widely quoted Category 1 status does not match the record. |
| PT-141 (compounded) | Not listed | Not on FDA’s 503A nominations list (updated 5/14/26) — in any category. The widely quoted Category 1 status does not match the record; no enforcement-discretion assurance attaches. |
| NAD+ | Discretion | Interim Category 1 — verified on FDA’s own nominations list (updated 5/14/26). Discretion, not approval, and revocable. |
| Glutathione | Discretion | Interim Category 1 — verified on FDA’s own list (updated 5/14/26). Note the Aug 19, 2026 nationwide recall of a compounded glutathione injection — Category 1 is not a safety rating. |
| Oxytocin | Not listed | Not on FDA’s 503A nominations list (updated 5/14/26) — in any category. The widely quoted Category 1 status does not match the record; no enforcement-discretion assurance attaches. |
| Ipamorelin | Unverified | Status inconsistent between sources. This board states no status until the record reconciles — that is what unverified means here. |
| Tesamorelin | Legal Rx | FDA-approved (Egrifta). Lawful with a valid prescription through licensed channels. |
| Bremelanotide | Legal Rx | FDA-approved (Vyleesi). Lawful with a valid prescription through licensed channels. |
Category 1 is discretion, not legality — FDA states it does not intend to take action
while review is pending, and can change position. FACT
Treat every green or amber row as dated the day you read it.
INTERPRETATION
The review docket
In the registry, verification in progress. No status is claimed for these — a substance joins the board only when its status has been verified against the record, with a source and a date.
CJC-1295GHRP-2GHRP-6Hexarelin
MGFTB4 fragmentGHK-CuMelanotan II
SelankDSIPKisspeptin-10LL-37
SS-31 (elamipretide)5-Amino-1MQRetatrutide (compounded)
TesofensineThymalinPinealon